Self-reported maternal adverse events of covid-19 vaccination during pregnancy
OBJECTIVE: To describe the self-reported maternal adverse events (AEs) of covid-19 vaccination during pregnancy.
DESIGN: The Dutch Pregnancy Drug Register ("Moeders van Morgen"), is a prospective cohort study among pregnant women in the Netherlands.
METHOD: Using online questionnaires, women reported whether they received a covid-19 vaccination and the self-perceived AEs after vaccination. We included women who received their first covid-19 vaccination during pregnancy. We assessed the maternal AEs by vaccine dose, type of vaccine (BioNTech/Pfizer, Moderna, AstraZeneca, and Janssen) and moment of vaccination in pregnancy.
RESULTS: 4348 women received their first covid-19 vaccination during pregnancy and were included. Of these, 2787 women also reported a second dose during pregnancy. After the first dose, AEs were less often reported for BioNTech/Pfizer (56% ≥1 AE), compared to Moderna (68% ≥1 AE) or AstraZeneca (87% ≥1 AE). After the second dose, AEs were less often reported for BioNTech/Pfizer (44% ≥1 AE) compared to Moderna (76% ≥1 AE). Injection site reactions, myalgia and fatigue were reported most frequently. There was large variation in the percentage reporting pyrexia/fever between the different vaccines (3%, 22%, and 10% after the second dose of BioNTech/Pfizer, Moderna, and Astrazeneca respectively). There were no major differences in the rates of AEs between vaccination in the first, second, or third trimester.
CONCLUSION: The adverse event profile among women who were vaccinated against covid-19 during pregnancy do not indicate any safety concerns. Considering the reported maternal AEs, the BioNTech/Pfizer vaccine seems best for vaccination during pregnancy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:166 |
|---|---|
| Enthalten in: |
Nederlands tijdschrift voor geneeskunde - 166(2022) vom: 22. Dez. |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
Maternale bijwerkingen na covid-19-vaccinatie in de zwangerschap |
|---|
| Beteiligte Personen: |
Woestenberg, Petra J [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 13.01.2023 Date Revised 16.02.2023 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM351439919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351439919 | ||
| 003 | DE-627 | ||
| 005 | 20231226051355.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351439919 | ||
| 035 | |a (NLM)36633023 | ||
| 035 | |a (PII)D6831 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a Woestenberg, Petra J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Self-reported maternal adverse events of covid-19 vaccination during pregnancy |
| 246 | 3 | 3 | |a Maternale bijwerkingen na covid-19-vaccinatie in de zwangerschap |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2023 | ||
| 500 | |a Date Revised 16.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To describe the self-reported maternal adverse events (AEs) of covid-19 vaccination during pregnancy | ||
| 520 | |a DESIGN: The Dutch Pregnancy Drug Register ("Moeders van Morgen"), is a prospective cohort study among pregnant women in the Netherlands | ||
| 520 | |a METHOD: Using online questionnaires, women reported whether they received a covid-19 vaccination and the self-perceived AEs after vaccination. We included women who received their first covid-19 vaccination during pregnancy. We assessed the maternal AEs by vaccine dose, type of vaccine (BioNTech/Pfizer, Moderna, AstraZeneca, and Janssen) and moment of vaccination in pregnancy | ||
| 520 | |a RESULTS: 4348 women received their first covid-19 vaccination during pregnancy and were included. Of these, 2787 women also reported a second dose during pregnancy. After the first dose, AEs were less often reported for BioNTech/Pfizer (56% ≥1 AE), compared to Moderna (68% ≥1 AE) or AstraZeneca (87% ≥1 AE). After the second dose, AEs were less often reported for BioNTech/Pfizer (44% ≥1 AE) compared to Moderna (76% ≥1 AE). Injection site reactions, myalgia and fatigue were reported most frequently. There was large variation in the percentage reporting pyrexia/fever between the different vaccines (3%, 22%, and 10% after the second dose of BioNTech/Pfizer, Moderna, and Astrazeneca respectively). There were no major differences in the rates of AEs between vaccination in the first, second, or third trimester | ||
| 520 | |a CONCLUSION: The adverse event profile among women who were vaccinated against covid-19 during pregnancy do not indicate any safety concerns. Considering the reported maternal AEs, the BioNTech/Pfizer vaccine seems best for vaccination during pregnancy | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Litjens, Carlijn H C |e verfasserin |4 aut | |
| 700 | 1 | |a Vissers, Lieke C M |e verfasserin |4 aut | |
| 700 | 1 | |a Kant, Agnes |e verfasserin |4 aut | |
| 700 | 1 | |a Berrens, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Vorstenbosch, Saskia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nederlands tijdschrift voor geneeskunde |d 1946 |g 166(2022) vom: 22. Dez. |w (DE-627)NLM000034231 |x 1876-8784 |7 nnns |
| 773 | 1 | 8 | |g volume:166 |g year:2022 |g day:22 |g month:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 166 |j 2022 |b 22 |c 12 | ||